🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Honored to be featured in nature to discuss how AI is quietly revolutionizing one of medicine’s most essential disciplines: pathology. Full article here: nature.com/articles/d4158… Pathology is the backbone of diagnosis, especially in cancer. But today, it faces immense strain

This is a major story from #ASCO25. Randomized phase 3 trial of time of day of immunotherapy infusion. Randomized to infusion before or after 3pm. Early infusion far superior: PFS 11.3 vs 5.7 HR 0.42, OS HR 0.45! Impactful, pragmatic, not costly. This should be a bigger story.

Real-world data = real insight. Let’s not underdose based on age alone. Bahadır Köylü, MD 👏 Congrats Bahadır & team! #ASCO25 #BreastCancer #GeriatricOncology #CDK46 #oncology Koç Üniversitesi Young SIOG @oncoalert ASCO

Congrats Koray & Hacettepe team on this elegant work at #ASCO25 Taha Koray Sahin Albumin-myosteatosis gauge (AMG): a new body composition biomarker to predict survival in ICI-treated patients. Low AMG = worse PFS & OS Hacettepe Üniversitesi #Oncology @oncoalert ASCO Emre Yekedüz

Was an honor chairing 🫁 orals with Pramesh CS #ASCO25 were in 30 min we saw more progress than we have seen in over 30 years for #SCLC #IMforte #DeLLphi-304 and #ZG006 TriTE!! Congratulations to all the presenters. This session had two NEJM one The Lancet and one Journal of Clinical Oncology !

#ASCO25 Is neoadjuvant platinum necessary in HER2+ eBC? 💥neoCARHP trial shows THP achieves pCR rates comparable to TCbHP 📌While EFS data are pending, growing evidence suggests carboplatin may be omitted after anthracyclines when dual HER2 blockade is used (Like HELEN-006)

🚨 Exercise is no longer optional, it is essential! One of the most impactful studies at #ASCO25 🏃‍♂️ The #CHALLENGE trial (LBA4319) proves that structured exercise after chemo in stage III colon cancer is not just lifestyle—it’s life-saving. 📊 5y DFS: 80.3% vs 73.9% ❤️ 8y OS:

NEW content online! Acquired resistance in cancer: towards targeted therapeutic strategies bit.ly/3SABwye

The landscape for radioligand therapies in oncology nature.com/articles/d4157… This article analyses the rapidly expanding landscape for radioligand therapies for cancer, including trends in technological advances and areas of application

How the gut microbiome could be useful as a biomarker for colon cancer screening nature.com/articles/s4159…

Time to Back to the ward. With more knowledge. More energy. More courage. Thank you #ASCO25 for 5 unforgettable days—full of learning, connection, and hope. See you soon 💙 ASCO OncoAlert #oncology #cancer Toni Choueiri, MD Emre Yekedüz Dana-Farber 𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏 Neeraj Agarwal, MD, FASCO

Delighted to have our work on Polygenic Modifiers of #TelomereBiologyDisorders, led by Michael Poeschla, along with Sasha Gusev, Mitchell Machiela, Sharon A. Savage, M.D., Tummala H, and others, published as an advanced online paper in Journal of Clinical Investigation today:

Neuro-immune crosstalk in cancer: mechanisms and therapeutic implications nature.com/articles/s4139…

Another Exercizumab study! 💪 Among 22,716 childhood cancer survivors: ⚠️ Obesity = ↑ risk of future cancers (solid, CNS, skin) 🏃‍♂️ Physical activity = protective effect across cancer types Lifestyle does matter, even decades later. #Survivorship #ChildhoodCancer #Prevention

Developmental dynamic transcriptomics reveals multiple effectors and transcription factors critical for Ditylenchus destructor parasitism biorxiv.org/content/10.110… #biorxiv_genomic

A nice review summarising lung cancer basic and translational research in 2025 #LCSM doi.org/10.1016/j.jtho… d.planchard Aɴᴛᴏɴɪᴏ Pᴀssᴀʀᴏ Benjamin Besse Sanjay Popat Giannis Mountzios Fred R. Hirsch Suresh S. Ramalingam, MD, FASCO Christine Lovly, MD, PhD, FASCO Hossein Borghaei, DO Joshua Reuss Chul Kim Biagio Ricciuti, MD, PhD

Ultimate review on Reirradiation. All that you need to know in one place. Must read!! doi.org/10.3322/caac.7… OncoAlert

Interesting phase 2 trial of 1L taxol/atezo/beva for (mostly) PDL1- mTNBC (n=100) out in Nature Medicine. ORR 63%, mPFS 11 months, mOS 27 months. VEGF inhibition is SO back in breast oncology. Glad to have had the chance to review this paper. nature.com/articles/s4159…

🚨Early bevacizumab dose and time modifications➡️ worse OS in advanced HCC treated with atezo-beva ESMO Gastrointestinal Oncology ⁦ESMO - Eur. Oncology⁩ #cancer #oncology #GI #liver esmogastro.org/article/S2949-…

Memleketin hakettiği güzel günlere ulaşmasını o kadar istiyorum ki, tüm samimiyetimle kişisel kariyerimde her şeyin tepe taklak olmasına bile razıyım. Çünkü biliyorum ki nefes aldığım ve sağlığım el verdiğince ben her zaman bir çıkış yolu bulurum ama organize rant ve kötülük,